ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
pi065509
|
165 |
35K |
10 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
165
|
35K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
9 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
396
|
85K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
6 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
396
|
85K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Louie the Beagle surpasses one year on MPL
|
|
pi065509
|
37 |
7.8K |
17 |
06/07/23 |
06/07/23 |
ASX - By Stock
|
37
|
7.8K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
10 |
06/07/23 |
06/07/23 |
ASX - By Stock
|
396
|
85K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
6 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
396
|
85K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
13 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
396
|
85K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
9 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
396
|
85K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
15 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
396
|
85K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
51 |
12K |
4 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
51
|
12K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
51 |
12K |
9 |
30/06/23 |
30/06/23 |
ASX - By Stock
|
51
|
12K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
pi065509
|
165 |
35K |
5 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
165
|
35K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Catalysts Before October to Enact The Options
|
|
pi065509
|
89 |
22K |
6 |
23/06/23 |
23/06/23 |
ASX - By Stock
|
89
|
22K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
pi065509
|
151 |
32K |
8 |
22/06/23 |
22/06/23 |
ASX - By Stock
|
151
|
32K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
pi065509
|
151 |
32K |
3 |
20/06/23 |
20/06/23 |
ASX - By Stock
|
151
|
32K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust MND Trial Interim Analysis PK Outcomes
|
|
pi065509
|
105 |
27K |
8 |
10/06/23 |
10/06/23 |
ASX - By Stock
|
105
|
27K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Catalysts Before October to Enact The Options
|
|
pi065509
|
89 |
22K |
15 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
89
|
22K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
pi065509
|
151 |
32K |
16 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
151
|
32K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
85 |
19K |
14 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
85
|
19K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
85 |
19K |
4 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
85
|
19K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Clinical Trial Update
|
|
pi065509
|
147 |
35K |
10 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
147
|
35K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
pi065509
|
88 |
17K |
2 |
27/05/23 |
27/05/23 |
ASX - By Stock
|
88
|
17K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
pi065509
|
88 |
17K |
7 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
88
|
17K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
pi065509
|
88 |
17K |
5 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
88
|
17K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
South Korean Biotech 2023
|
|
pi065509
|
46 |
9.7K |
9 |
24/05/23 |
24/05/23 |
ASX - By Stock
|
46
|
9.7K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Clinical Trial Update
|
|
pi065509
|
147 |
35K |
6 |
24/05/23 |
24/05/23 |
ASX - By Stock
|
147
|
35K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
South Korean Biotech 2023
|
|
pi065509
|
46 |
9.7K |
4 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
46
|
9.7K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
South Korean Biotech 2023
|
|
pi065509
|
46 |
9.7K |
6 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
46
|
9.7K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Price manipulation
|
|
pi065509
|
35 |
8.2K |
2 |
22/05/23 |
22/05/23 |
ASX - By Stock
|
35
|
8.2K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Progress update on Phase 1/2 MND interim analysis
|
|
pi065509
|
65 |
17K |
2 |
22/05/23 |
22/05/23 |
ASX - By Stock
|
65
|
17K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 3Y
|
|
pi065509
|
2 |
731 |
5 |
11/05/23 |
11/05/23 |
ASX - By Stock
|
2
|
731
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
MONEPANTEL - A Pan-Cancer Wonder Drug
|
|
pi065509
|
84 |
22K |
6 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
84
|
22K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Raises $2.5m via Placement
|
|
pi065509
|
138 |
29K |
4 |
03/05/23 |
03/05/23 |
ASX - By Stock
|
138
|
29K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Completes Enrolment of Cohort 2
|
|
pi065509
|
104 |
28K |
17 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
104
|
28K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Investor Webinar Presentation
|
|
pi065509
|
92 |
19K |
7 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
92
|
19K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Investor Webinar Presentation
|
|
pi065509
|
92 |
19K |
12 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
92
|
19K
|
12
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Change of Share Registry Details
|
|
pi065509
|
3 |
1.8K |
4 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
3
|
1.8K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Cancer Trial Update
|
|
pi065509
|
220 |
43K |
6 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
220
|
43K
|
6
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
6 |
12/03/23 |
12/03/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Bella's Monepantel Trial
|
|
pi065509
|
127 |
28K |
9 |
10/03/23 |
10/03/23 |
ASX - By Stock
|
127
|
28K
|
9
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
7 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Cancer Trial Update
|
|
pi065509
|
220 |
43K |
21 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
220
|
43K
|
21
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
9 |
06/03/23 |
06/03/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Interim analysis recommended in MND trial
|
|
pi065509
|
71 |
19K |
7 |
03/03/23 |
03/03/23 |
ASX - By Stock
|
71
|
19K
|
7
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
1 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient of Cohort 2 Dosed in MND Trial
|
|
pi065509
|
79 |
19K |
5 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
79
|
19K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient of Cohort 2 Dosed in MND Trial
|
|
pi065509
|
79 |
19K |
6 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
79
|
19K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient of Cohort 2 Dosed in MND Trial
|
|
pi065509
|
79 |
19K |
14 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
79
|
19K
|
14
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
2 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Interactive AGM Yes/No vote
|
|
pi065509
|
87 |
13K |
4 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
87
|
13K
|
4
|
|